Litigation Details for Horizon Therapeutics Inc v. Par Pharmaceutical Inc (E.D. Tex. 2014)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2014-04-23
Court	District Court, E.D. Texas	Date Terminated	2018-08-09
Cause	15:1126 Patent Infringement	Assigned To	James Rodney Gilstrap
Jury Demand	None	Referred To	Roy S. Payne
Parties	HORIZON THERAPEUTICS INC
Patents	8,404,215; 8,642,012
Attorneys	George F Pappas
Firms	Axinn, Veltrop & Harkrider, LLP - Washington
Link to Docket	External link to docket

The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2014-04-23	1		United States Patent Nos. 8,404,215 (“the ’215 patent”) and 8,642,012 (“the ’012 patent”) (collectively… This is a civil action for patent infringement arising under the patent laws of the United States, …, FDA has listed United States Patent No. 5,968,979 (“the ’979 patent”), in connection with NDA No. 20…the United States Patent and Trademark Office duly and legally issued the ’215 patent, entitled “Methods…of the ’215 patent runs through March 9, 2032. A true and correct copy of the ’215 patent is attached	External link to document
2015-10-20	129		in two asserted patents: U.S. Patent No. 8,404,215 (“the ’215 patent”) and U.S. Patent No. 8,642,012 (… for the disputed terms of U.S. Patent No. 8,404,215 and U.S. Patent No. 8,642,012. The parties are ORDERED…BACKGROUND AND THE ASSERTED PATENTS The ’215 patent and the ’012 patent describe methods for treating…ammonia level in the patent.” (’012 patent col. 42, ll. 60–62.) The ’012 patent defines the term “normal… enzymes or 1 The ’215 patent issued on March 26, 2013. The ’215 patent was filed on March 9, 2012	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document